

2023 Regular Session

HOUSE BILL NO. 403

BY REPRESENTATIVE BROWN

1
2
3
4
5
6
7
8
9
10
11
12
13

AN ACT

To amend and reenact R.S. 22:1053(A)(2), relative to coverage of step therapy or fail first protocols; to authorize substitution of biosimilar biological products designated by the federal Food and Drug Administration; and to provide for related matters.

Be it enacted by the Legislature of Louisiana:

Section 1. R.S. 22:1053(A)(2) is hereby amended and reenacted to read as follows:
§1053. Requirement for coverage of step therapy or fail first protocols

A.

* * *

(2) The provisions of this Section shall not be construed to prohibit the substitution of an AB-rated generic equivalent, biosimilar, or interchangeable biological product as designated by the federal Food and Drug Administration.

* * *

SPEAKER OF THE HOUSE OF REPRESENTATIVES

PRESIDENT OF THE SENATE

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____